

Next Science SPP Offer Opens

Sydney, Australia Friday, 1 September 2023, Next Science Limited (ASX: NXS) (**Next Science** or the **Company**), a medical technology company focused on commercialising its proprietary XBIO™ suite of products to reduce the impact of biofilm-based infections in human health, is pleased to announce the opening of the Next Science Share Purchase Plan Offer.

Next Science announced on 31 August 2023 that it would be undertaking a share purchase plan (**SPP**). The SPP is now open to eligible Next Science shareholders to apply for up to A\$30,000 of new fully paid ordinary shares in Next Science (**SPP Shares**) without incurring brokerage or other transaction costs.

The SPP follows the successful completion of a placement to institutional and sophisticated investors and an agreement to retire the A\$10m convertible notes held by Walker Group in return for equity at an issue price of A\$0.42 per share, subject to shareholder approval, as announced on 31 August 2023.

Eligibility

Shareholders are eligible to participate in the SPP if:

- (i) they had a registered address in Australia or New Zealand on Next Science's share register as at 7.00pm (Sydney time) on Wednesday, 30 August 2023; and
- (ii) if their registered address is in New Zealand, they continued to hold shares from the Record Date to the Opening Date.

Shareholders who hold shares on behalf of, or who act for the account or benefit of, persons who reside outside Australia or New Zealand including persons who are in the United States, are not entitled to participate in the SPP.

The SPP Offer

SPP Shares are being offered at the issue price under the placement announced to the market on 31 August 2023 (being A\$0.42).

The SPP is aiming to raise up to A\$5m. In the event of oversubscriptions, the SPP may be subject to a scale back of applications at the discretion of the Company.

SPP Shares will rank equally with existing Next Science fully paid ordinary shares on issue.

Participation in the SPP is voluntary.

Offer Booklet

Participation in the SPP is subject to the terms and conditions set out in the SPP Offer Booklet. Eligible Shareholders are encouraged to read the Offer Booklet.

NEXT SCIENCE®

The Offer Booklet is **attached** and will be dispatched by email today to those shareholders who have elected to receive electronic communications and by post on or about Wednesday, 6 September 2023 to those shareholders who have not made such an election.

Eligible shareholders may apply online from today via the Next Science SPP Offer website at: <https://spp.nextscience.com/>

Eligible shareholders can also access the SPP Offer site by scanning the QR Code below with their smart device:



Indicative Timetable**

Event	Date, 2023
Record Date for the SPP	7.00pm Wednesday, 30 August
Announcement of SPP	Thursday, 31 August
Opening - SPP and US Placement	Friday, 1 September
Settlement of the Institutional Placement	Tuesday, 5 September
Allotment of New Shares under the Institutional Placement	Wednesday, 6 September
Closing Date - SPP and US Placement	Monday, 18 September
Allotment of New Shares under the SPP and US Placement	By Monday, 25 September
Shareholder Meeting to approve the issue of shares to Next Science substantial holder, Walker Group, and Director participation in the Placement	Est. late October
Issue of Walker Subscription Shares and Director Placement Shares	5 Business Days after the Meeting

*** These dates are indicative only and are subject to change. Next Science reserves the right, subject to the Corporations Act 2001 (Cth) and the ASX Listing Rules, to amend this indicative timetable. In particular, Next Science reserves the right to extend the Closing Date, accept late applications under the SPP Offer (either generally or in particular cases), and to withdraw or vary the Placement, the US Placement or SPP Offer without prior notice. Any extension of the closing date will have a consequential effect on the date for the allotment and issue of New Shares. The timetable in respect of the Placement can only be amended by Next Science with the agreement of the Lead Managers.*

NEXT SCIENCE®

Further Information:

Martyn Jacobs

Head of Investor Relations

Phone: +61 412 785 180

Email: mjacobs@nextscience.com

Approved and authorised for release by the Managing Director and CEO.

About Next Science

Next Science is a medical technology company headquartered in Sydney, Australia, with a research and development centre in Florida, USA. Established in 2012, the company's primary focus is on the development and continued commercialisation of its proprietary XBIO™ technology to reduce the impact of biofilm-based infections in human health. XBIO™ is a unique, non-toxic technology with proven efficacy in eradicating both biofilm-based and free-floating bacteria. Next Science owns 100% of the patent protected intellectual property relating to its XBIO™ technology. For further information visit: www.nextscience.com